Newborn Screening for Sickle Cell Disease: Effect on Mortality

¹ From the Department of Hematology/Oncology, Children's Hospital, Oakland, California

Newborn screening for sickle cell disease has been recommended as a method of decreasing patient mortality. However, its effectiveness in accomplishing this has not been reliably measured. To help determine the effectiveness, 10 years of experience in newborn screening have been summarized. The effects of early patient enrollment in a comprehensive treatment program on long-term morbidity and mortality are reported. From 1975 to 1985, 84,663 newborns were screened regardless of race or ethnic background. Bart's hemoglobin was present in 5%, hemoglobin AS in 2.6%, and hemoglobin AC in 0.75%. Excluding Bart's, approximately 3.6% of all newborns were carriers for hemoglobinopathy. Sickle cell disease occurred in 1:951 births (58 hemoglobin SS, 25 hemoglobin FSC, three hemoglobin S-⁺-thalassemia, and three hemoglobin S-°-thalassemia). In addition, one in every 4,233 newborns had a clinically significant thalassemia syndrome (eight hemoglobin FE, ten hemoglobin F only, two hemoglobin H). Compared with other newborn screening programs in California, (congenital hypothyroidism, 1:3,849; phenylketonuria 1:22,474, galactosemia 1:74,103), hemoglobinopathies are the most prevalent congenital disease. Eighty-one newborns with sickle cell disease were followed for 7.2 years. Patients experienced 513 hospitalizations, including 13 episodes of sepsis with or without meningitis and ten acute sequestration crises. The overall mortality rate for patients with sickle cell anemia diagnosed in the newborn period was 1.8%. In comparison, the clinical course of 64 patients with sickle cell anemia diagnosed after 3 months of age and followed for an average of 9.4 years was analyzed. Five of these patients died. In two of these, sickle cell anemia was diagnosed at the time of the death. Overall mortality rate in this group was 8%. In summary, the data indicate that newborn screening, when coupled with extensive follow-up and education, will significantly decrease patient mortality.

Key Words: newborn screening • sickle cell disease • sepsis • anemia • hemoglobinopathy

Submitted on November 5, 1987
Accepted on January 4, 1988

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M C Rahimy, A Gangbo, G Ahouignan, and E Alihonou Newborn screening for sickle cell disease in the Republic of Benin J. Clin. Pathol., January 1, 2009; 62(1): 46 - 48. [Abstract] [Full Text] [PDF]

				B J Bain Neonatal/newborn haemoglobinopathy screening in Europe and Africa J. Clin. Pathol., January 1, 2009; 62(1): 53 - 56. [Abstract] [Full Text] [PDF]

				F. Boemer, O. Ketelslegers, J.-M. Minon, V. Bours, and R. Schoos Newborn Screening for Sickle Cell Disease Using Tandem Mass Spectrometry Clin. Chem., December 1, 2008; 54(12): 2036 - 2041. [Abstract] [Full Text] [PDF]

				I. Roberts and M. de Montalembert Sickle cell disease as a paradigm of immigration hematology: new challenges for hematologists in Europe Haematologica, July 1, 2007; 92(7): 865 - 871. [Full Text] [PDF]

				C. T. Quinn, Z. R. Rogers, and G. R. Buchanan Survival of children with sickle cell disease Blood, June 1, 2004; 103(11): 4023 - 4027. [Abstract] [Full Text] [PDF]

				S. Claster and E. P Vichinsky Managing sickle cell disease BMJ, November 15, 2003; 327(7424): 1151 - 1155. [Full Text] [PDF]

				M. C. Rahimy, A. Gangbo, G. Ahouignan, R. Adjou, C. Deguenon, S. Goussanou, and E. Alihonou Effect of a comprehensive clinical care program on disease course in severely ill children with sickle cell anemia in a sub-Saharan African setting Blood, August 1, 2003; 102(3): 834 - 838. [Abstract] [Full Text] [PDF]

				Section on Hematology/Oncology and Committee on Ge Health Supervision for Children with Sickle Cell Disease Pediatrics, March 1, 2002; 109(3): 526 - 535. [Abstract] [Full Text] [PDF]

				M. Campbell, J. S. Henthorn, and S. C. Davies Evaluation of Cation-Exchange HPLC Compared with Isoelectric Focusing for Neonatal Hemoglobinopathy Screening Clin. Chem., July 1, 1999; 45(7): 969 - 975. [Abstract] [Full Text] [PDF]

				M. H. Steinberg Management of Sickle Cell Disease N. Engl. J. Med., April 1, 1999; 340(13): 1021 - 1030. [Full Text] [PDF]

				N. A. Holtzman, P. D. Murphy, M. S. Watson, and P. A. Barr Predictive Genetic Testing: From Basic Research to Clinical Practice Science, October 24, 1997; 278(5338): 602 - 605. [Abstract] [Full Text]

				A. K. Brown, L. A. Sleeper, S. T. Miller, C. H. Pegelow, F. M. Gill, and M. A. Waclawiw Reference Values and Hematologic Changes From Birth to 5 Years in Patients With Sickle Cell Disease Arch Pediatr Adolesc Med, August 1, 1994; 148(8): 796 - 804. [Abstract] [PDF]

				R. H. Sprinkle, D. M. Hynes, and T. R. Konrad Is Universal Neonatal Hemoglobinopathy Screening Cost-Effective? Arch Pediatr Adolesc Med, May 1, 1994; 148(5): 461 - 469. [Abstract] [PDF]

				B. Houser, H. M. Plawecki, J. Carr, M. A. Smith, and J. A. Plawecki A Holistic Approach to Vaso-Occlusive Pain Crisis in Children With Sickle Cell Disease J Holist Nurs, March 1, 1992; 10(1): 62 - 75. [Abstract] [PDF]

				S. T. Miller, T. V. Stilerman, S. P. Rao, S. Abhyankar, and A. K. Brown Newborn Screening for Sickle Cell Disease: When Is an Infant 'Lost to Follow-up'? Arch Pediatr Adolesc Med, December 1, 1990; 144(12): 1343 - 1345. [Abstract] [PDF]

				J. H. Githens, P. A. Lane, R. S. McCurdy, M. L. Houston, J. D. McKinna, and D. M. Cole Newborn Screening for Hemoglobinopathies in Colorado: The First 10 Years Arch Pediatr Adolesc Med, April 1, 1990; 144(4): 466 - 470. [Abstract] [PDF]